Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections
· Preparations for Phase 3 study progressing to plan
· Established world leading clinical advisory board
· Partnering discussions ongoing
Brighton, United Kingdom – 2nd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, is pleased to announce positive progress with its lead clinical programme, NTCD-M3.